Rocheusa ( Rocheusa )

Rocheusa

Rocheusa's picture

Roche AG is a Swiss multinational health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has bearer shares listed on the SIX Swiss Exchange.

Rocheusa press release, blog etc

02/15/2018 - 11:08 Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer
02/07/2018 - 22:23 Roche purchases shares in tender offer for Ignyta, Inc.
02/05/2018 - 23:05 Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
02/01/2018 - 00:34 Roche reports good results in 2017
01/26/2018 - 01:32 CHMP recommends EU approval of Roches Hemlibra for people with haemophilia A with inhibitors
01/12/2018 - 00:59 Roches OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis
01/10/2018 - 00:03 Roche commences tender offer for all shares of Ignyta, Inc. for US$ 27.00 per share in cash
01/08/2018 - 01:51 Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment
01/04/2018 - 11:05 Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas
12/21/2017 - 23:53 Roche and Ignyta reach definitive merger agreement
12/20/2017 - 23:01 FDA approves Roches Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer
12/20/2017 - 22:41 European Commission approves Roches Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
12/10/2017 - 23:29 Phase III IMmotion151 study showed Roches Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer
12/10/2017 - 05:42 Phase II data showed Roches investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma
12/09/2017 - 05:14 Roches Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors
12/06/2017 - 20:46 Roches Hemlibra every four weeks controlled bleeds in phase III study in haemophilia A
12/03/2017 - 22:44 FDA approves Foundation Medicines FoundationOne CDx, the first pan-tumour comprehensive genomic profiling assay incorporating a broad range of companion diagnostics
11/19/2017 - 23:51 Roches Hemlibra significantly reduced bleeds in phase III study in haemophilia A